表紙
市場調査レポート

Boston Biomedical, Inc. - 製品パイプライン分析

Boston Biomedical, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256110
出版日 ページ情報 英文 31 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Boston Biomedical, Inc. - 製品パイプライン分析 Boston Biomedical, Inc. - Product Pipeline Review - 2015
出版日: 2015年05月27日 ページ情報: 英文 31 Pages
概要

Boston Biomedical, Inc. は、新たな癌治療薬開発に取り組むバイオテクノロジー企業です。同社は創薬、結晶学、医薬品化学、前臨床開発、薬理学、医薬開発、世界中での臨床試験、薬事規制など、癌の治療薬研究を進めてきました。その結果、 癌に関して10を超える創薬段階プログラム、5つ以上の臨床段階プログラムを開発してきました。

当レポートでは、Boston Biomedical, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Boston Biomedical, Inc.の基本情報

Boston Biomedical, Inc.の概要

  • 主要情報
  • 企業情報

Boston Biomedical, Inc.:R&Dの概要

  • 主な治療範囲

Boston Biomedical, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Boston Biomedical, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨段階にある製品/併用療法モダリティ

Boston Biomedical, Inc.:薬剤プロファイル

  • BBI-608
  • BBI-503
  • Cancer Stem Cells for Oncology

Boston Biomedical, Inc.:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Boston Biomedical, Inc.:最近のパイプライン動向

Boston Biomedical, Inc.:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07138CDB

Summary

Global Markets Direct's, 'Boston Biomedical, Inc. - Product Pipeline Review - 2015', provides an overview of the Boston Biomedical, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boston Biomedical, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Boston Biomedical, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Boston Biomedical, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Boston Biomedical, Inc.'s pipeline products

Reasons to buy

  • Evaluate Boston Biomedical, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Boston Biomedical, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Boston Biomedical, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Boston Biomedical, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Boston Biomedical, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Boston Biomedical, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Boston Biomedical, Inc. Snapshot
    • Boston Biomedical, Inc. Overview
    • Key Information
    • Key Facts
  • Boston Biomedical, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Boston Biomedical, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Boston Biomedical, Inc. - Pipeline Products Glance
    • Boston Biomedical, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Boston Biomedical, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Boston Biomedical, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Boston Biomedical, Inc. - Drug Profiles
    • napabucasin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBI-503
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • napabucasin + BBI-503
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules targeting Cancer Stem Cells for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Boston Biomedical, Inc. - Pipeline Analysis
    • Boston Biomedical, Inc. - Pipeline Products by Target
    • Boston Biomedical, Inc. - Pipeline Products by Route of Administration
    • Boston Biomedical, Inc. - Pipeline Products by Molecule Type
    • Boston Biomedical, Inc. - Pipeline Products by Mechanism of Action
  • Boston Biomedical, Inc. - Recent Pipeline Updates
  • Boston Biomedical, Inc. - Dormant Projects
  • Boston Biomedical, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Boston Biomedical, Inc., Key Information
  • Boston Biomedical, Inc., Key Facts
  • Boston Biomedical, Inc. - Pipeline by Indication, 2015
  • Boston Biomedical, Inc. - Pipeline by Stage of Development, 2015
  • Boston Biomedical, Inc. - Monotherapy Products in Pipeline, 2015
  • Boston Biomedical, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Boston Biomedical, Inc. - Phase III, 2015
  • Boston Biomedical, Inc. - Phase II, 2015
  • Boston Biomedical, Inc. - Phase I, 2015
  • Boston Biomedical, Inc. - Preclinical, 2015
  • Boston Biomedical, Inc. - Pipeline by Target, 2015
  • Boston Biomedical, Inc. - Pipeline by Route of Administration, 2015
  • Boston Biomedical, Inc. - Pipeline by Molecule Type, 2015
  • Boston Biomedical, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Boston Biomedical, Inc. - Recent Pipeline Updates, 2015
  • Boston Biomedical, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Boston Biomedical, Inc. - Pipeline by Top 10 Indication, 2015
  • Boston Biomedical, Inc. - Pipeline by Stage of Development, 2015
  • Boston Biomedical, Inc. - Monotherapy Products in Pipeline, 2015
  • Boston Biomedical, Inc. - Pipeline by Top 10 Target, 2015
  • Boston Biomedical, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Boston Biomedical, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Boston Biomedical, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top